Is there a future for prenyltransferase inhibitors in cancer therapy?

Current Opinion in Pharmacology

Volumn 12, Issue 6, 2012, Pages 704-709

  Holstein, Sarah A ^a   Hohl, Raymond J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CYTARABINE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GERANYLGERANYL TRANSFERASE INHIBITOR; GGTI 2418; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; K RAS PROTEIN; L 778123; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N RAS PROTEIN; PACLITAXEL; PRENYLTRANSFERASE INHIBITOR; RAS PROTEIN; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TIPIFARNIB; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADVANCED CANCER; APTX GENE; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CHILDHOOD LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FTASE ALPHA GENE; FTASE BETA GENE; GENE; GENE EXPRESSION; GENETIC SCREENING; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERLIPIDEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PONTINE GLIOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN PRENYLATION; PROTEIN PROCESSING; PRURITUS; SOLID TUMOR; T CELL LYMPHOMA; THYROID CANCER; TREATMENT RESPONSE;

EID: 84870505131     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.06.013     Document Type: Review

References (39)

1. S.M. Sebti Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy Cancer Cell 7 2005 297 300
2. Z. Guo, Y.W. Wu, D. Das, C. Delon, J. Cramer, S. Yu, S. Thuns, N. Lupilova, H. Waldmann, and L. Brunsveld Structures of RabGGTase-substrate/ product complexes provide insights into the evolution of protein prenylation EMBO J 27 2008 2444 2456
3. C.A. Rowell, J.J. Kowalczyk, M.D. Lewis, and A.M. Garcia Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo J Biol Chem 272 1997 14093 14097
4. D.B. Whyte, P. Kirschmeier, T.N. Hockenberry, I. Nunez-Oliva, L. James, J.J. Catino, W.R. Bishop, and J.K. Pai K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272 1997 14459 14464
5. E.C. Lerner, T.T. Zhang, D.B. Knowles, Y. Qian, A.D. Hamilton, and S.M. Sebti Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene 15 1997 1283 1288
6. J. Sun, Y. Qian, A.D. Hamilton, and S.M. Sebti Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts Oncogene 16 1998 1467 1473
7. C.A. Omer, Z. Chen, R.E. Diehl, M.W. Conner, H.Y. Chen, M.E. Trumbauer, S. Gopal-Truter, G. Seeburger, H. Bhimnathwala, and M.T. Abrams Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor Cancer Res 60 2000 2680 2688
8. N.E. Kohl, F.R. Wilson, S.D. Mosser, E. Giuliani, S.J. deSolms, M.W. Conner, N.J. Anthony, W.J. Holtz, R.P. Gomez, and T.J. Lee Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice Proc Natl Acad Sci U S A 91 1994 9141 9145
9. A.D. Basso, A. Mirza, G. Liu, B.J. Long, W.R. Bishop, and P. Kirschmeier The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity J Biol Chem 280 2005 31101 31108
10. A.F. Castro, J.F. Rebhun, G.J. Clark, and L.A. Quilliam Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner J Biol Chem 278 2003 32493 32496
11. H.E. Huber, R.G. Robinson, A. Watkins, D.D. Nahas, M.T. Abrams, C.A. Buser, R.B. Lobell, D. Patrick, N.J. Anthony, and C.J. Dinsmore Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors J Biol Chem 276 2001 24457 24465
12. N. Berndt, A.D. Hamilton, and S.M. Sebti Targeting protein prenylation for cancer therapy Nat Rev Cancer 11 2011 775 791
13. T.E. Witzig, H. Tang, I.N. Micallef, S.M. Ansell, B.K. Link, D.J. Inwards, L.F. Porrata, P.B. Johnston, J.P. Colgan, and S.N. Markovic Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas Blood 118 2011 4882 4889
14. J. Kauh, C. Chanel-Vos, D. Escuin, M.P. Fanucchi, R.D. Harvey, N. Saba, D.M. Shin, A. Gal, L. Pan, and M. Kutner Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies Cancer 117 2011 4049 4059
15. F. Dalenc, S.F. Doisneau-Sixou, B.C. Allal, S. Marsili, V. Lauwers-Cances, K. Chaoui, O. Schiltz, B. Monsarrat, T. Filleron, and N. Renee Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis Clin Cancer Res 16 2010 1264 1271
16. M. Raponi, J.E. Lancet, H. Fan, L. Dossey, G. Lee, I. Gojo, E.J. Feldman, J. Gotlib, L.E. Morris, and P.L. Greenberg A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia Blood 111 2008 2589 2596
17. J.E. Karp, T.I. Vener, M. Raponi, E.K. Ritchie, B.D. Smith, S.D. Gore, L.E. Morris, E.J. Feldman, J.M. Greer, and S. Malek Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia Blood 119 2012 55 63
18. D. Rolland, V. Ribrag, C. Haioun, H. Ghesquieres, F. Jardin, R. Bouabdallah, P. Franchi, J. Briere, E. De Kerviler, and C. Chassagne-Clement Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial Cancer Chemother Pharmacol 65 2010 781 790
19. P.J. O'Dwyer, M. Gallagher, B. Nguyen, M.J. Waddell, and E.G. Chiorean Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors Ann Oncol 21 2010 ii42
20. S.A. Holstein, and R.J. Hohl Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells Leuk Res 35 2011 551 559
21. A. Barbarin, and R. Frade Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cells Biochem J 437 2011 97 107
22. P.S. Yang, P.H. Yin, L.M. Tseng, C.H. Yang, C.Y. Hsu, M.Y. Lee, C.F. Horng, and C.W. Chi Rab5A is associated with axillary lymph node metastasis in breast cancer patients Cancer Sci 102 2011 2172 2178
23. A. Hendrix, G. Braems, M. Bracke, M. Seabra, W. Gahl, O. De Wever, and W. Westbroek The secretory small GTPase Rab27B as a marker for breast cancer progression Oncotarget 1 2010 304 308
24. A. Hendrix, D. Maynard, P. Pauwels, G. Braems, H. Denys, R. Van den Broecke, J. Lambert, S. Van Belle, V. Cocquyt, and C. Gespach Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis J Natl Cancer Inst 102 2010 866 880
25. K.W. Cheng, J.P. Lahad, W.L. Kuo, A. Lapuk, K. Yamada, N. Auersperg, J. Liu, K. Smith-McCune, K.H. Lu, and D. Fishman The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers Nat Med 10 2004 1251 1256
26. S.A. Holstein The isoprenoid biosynthetic pathway and statins C.A. Hrycyna, M.O. Bergo, F. Tamanoi, The Enzymes 2011 Elsevier 279 299
27. S.A. Holstein, and R.J. Hohl Inhibition of farnesyl and geranylgeranyl diphosphate synthases C.A. Hrycyna, M.O. Bergo, F. Tamanoi, The Enzymes 2011 Elsevier 301 319
28. A.J. Wiemer, D.F. Wiemer, and R.J. Hohl Geranylgeranyl diphosphate synthase: an emerging therapeutic target Clin Pharmacol Ther 90 2011 804 812
29. B.C. Widemann, R.J. Arceci, N. Jayaprakash, E. Fox, P. Zannikos, W. Goodspeed, A. Goodwin, J.J. Wright, S.M. Blaney, and P.C. Adamson Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group Pediatr Blood Cancer 56 2011 226 233
30. T. Li, M. Guo, W.J. Gradishar, J.A. Sparano, E.A. Perez, M. Wang, and G.W. Sledge A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103) Breast Cancer Res Treat 2012 [Epub ahead of print]
31. J.E. Lancet, V.H. Duong, E.F. Winton, R.K. Stuart, M. Burton, S. Zhang, C. Cubitt, M.A. Blaskovich, J.J. Wright, and S. Sebti A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias Clin Cancer Res 17 2011 1140 1146
32. E. Jabbour, H. Kantarjian, F. Ravandi, G. Garcia-Manero, Z. Estrov, S. Verstovsek, S. O'Brien, S. Faderl, D.A. Thomas, and J.J. Wright A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome Cancer 117 2011 1236 1244
33. D.S. Hong, M.E. Cabanillas, J. Wheler, A. Naing, A.M. Tsimberidou, L. Ye, S.G. Waguespack, M. Hernandez, A.K. El Naggar, and S. Bidyasar Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies J Clin Endocrinol Metab 96 2011 997 1005
34. K.A. Margolin, J. Moon, L.E. Flaherty, C.D. Lao, W.L. Akerley 3rd, M. Othus, J.A. Sosman, J.M. Kirkwood, and V.K. Sondak Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438) Clin Cancer Res 18 2012 1129 1137
35. D.A. Haas-Kogan, A. Banerjee, T.Y. Poussaint, M. Kocak, M.D. Prados, J.R. Geyer, M. Fouladi, A. Broniscer, J.E. Minturn, and I.F. Pollack Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas Neuro Oncol 13 2011 298 306
36. C. Castaneda, K.L. Meadows, R. Truax, M.A. Morse, S.H. Kaufmann, W.P. Petros, Y. Zhu, P. Statkevich, D.L. Cutler, and H.I. Hurwitz Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors Cancer Chemother Pharmacol 67 2011 455 463
37. A. Desjardins, D.A. Reardon, K.B. Peters, S. Threatt, A.D. Coan, J.E. Herndon 2nd, A.H. Friedman, H.S. Friedman, and J.J. Vredenburgh A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma J Neurooncol 105 2011 601 606
38. W. Meier, A. du Bois, J. Rau, M. Gropp-Meier, K. Baumann, J. Huober, K. Wollschlaeger, R. Kreienberg, U. Canzler, and B. Schmalfeldt Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV Gynecol Oncol 126 2012 236 240
39. N.S. Wong, K.L. Meadows, L.S. Rosen, A.A. Adjei, S.H. Kaufmann, M.A. Morse, W.P. Petros, Y. Zhu, P. Statkevich, and D.L. Cutler A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer Cancer Invest 29 2011 617 625